BioPharmSignal logoBioPharmSignal

Biotech News

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

Pulmonx (LUNG)PulmonxConference / presentation

REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 46 th Annual Growth

Related news

PLSEPulse Biosciences2026-07-30 20:05 EST

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

CVRXCVRx2026-07-28 12:30 EST

CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference

XTNTXtant Medical2026-08-04 20:05 EST

Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference

DCTHDelcath Systems2026-07-28 20:01 EST

Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference

APYXApyx Medical2026-07-28 12:00 EST

Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference

IARTIntegra LifeSciences2026-09-04 13:15 EST

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

SGHTSight Sciences2026-09-01 20:05 EST

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15

ADPTAdaptive Biotechnologies2026-09-01 20:05 EST

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

ATRCAtriCure2026-08-25 12:00 EST

AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

ICUSeaStar Medical2026-09-10 12:35 EST

SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference

View all latest news

Pulmonx

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

LUNGPulmonx2026-09-01 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-08-27 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

LUNGPulmonx2026-07-15 20:05 EST

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

Stock data

Close
2.07 USD
Market cap
68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States